

Specialty Guideline Management-FEHB

Aveed

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
|------------|--------------------------|
| Aveed | testosterone undecanoate |

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications¹

Aveed is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

- Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

| Reference number(s) |
|---------------------|
| 6991-A |

Aveed should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of pulmonary oil microembolism (POME) and anaphylaxis.

Limitations of Use

- Safety and efficacy of Aveed in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
- Safety and efficacy of Aveed in males less than 18 years old have not been established.

Compendial Uses³⁻⁶

Gender dysphoria (also known as transgender and gender diverse [TGD] persons)

All other indications are considered experimental/investigational and not medically necessary.

Documentation

The following information is necessary to initiate the prior authorization review: For primary hypogonadism or hypogonadotropic hypogonadism, pretreatment morning serum total testosterone concentrations.

Exclusions

Coverage will not be provided for members with any of the following exclusions: use for age-related hypogonadism or late-onset hypogonadism.

Coverage Criteria

Primary Hypogonadism or Hypogonadotropic Hypogonadism^{1,2}

Authorization of 12 months may be granted for treatment of primary hypogonadism or hypogonadotropic hypogonadism when all of the following criteria are met:

- Member is a biological male or a person that self identifies as male.
- Member is at least 18 years of age.
- Member has at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines.

Gender Dysphoria^{3-6,8}

Authorization of 12 months may be granted for gender dysphoria when all of the following criteria are met:

- The member has a diagnosis of gender dysphoria.

- Member is at least 19 years of age or older.
- The member is able to make an informed decision to engage in hormone therapy.
- The member's comorbid conditions are reasonably controlled.
- The member has been educated on any contraindications and side effects to therapy.
- The member has been informed of fertility preservation options.

Continuation of Therapy

Primary Hypogonadism or Hypogonadotropic Hypogonadism

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for primary hypogonadism or hypogonadotropic hypogonadism when all of the following criteria are met:

- Member is a biological male or a person that self identifies as male.
- Member is at least 18 years of age.
- Before the start of therapy, the member had at least two confirmed low morning serum total testosterone concentrations based on the reference laboratory range or current practice guidelines.

Gender Dysphoria⁸

Authorization of 12 months may be granted for continued treatment for gender dysphoria in members requesting reauthorization when all of the following criteria are met:

- The member has a diagnosis of gender dysphoria.
- Member is at least 19 years of age or older.
- The member is able to make an informed decision to engage in hormone therapy.
- The member's comorbid conditions are reasonably controlled.
- The member has been educated on any contraindications and side effects to therapy.
- Before the start of therapy, the member has been informed of fertility preservation options.

References

1. Aveed [package insert]. Malvern, PA: Endo USA; August 2021.
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
3. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903.
4. Gender Identity Research and Education Society. Guidance for GPs and other clinicians on the treatment of gender variant people. UK Department of Health. Published March 10, 2008.

| Reference number(s) |
|---------------------|
| 6991-A |

5. Coleman E, Radix AE, Brown GR, et al. Standards of care for the health of transgender and gender diverse people, version 8. 2022;23(Suppl 1):S1-S259. doi: 10.1080/26895269.2022.2100644
6. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com/> (cited: February 14, 2025).
7. Health Care for Transgender and Gender Diverse Individuals. ©2021 The American College of Obstetricians and Gynecologists. Available at: <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/03/health-care-for-transgender-and-gender-diverse-individuals>.
8. FEHB Program Carrier Letter. Letter Number 2025-01A. <https://www.opm.gov/healthcare-insurance/carriers/fehb/2025/2025-1a.pdf>. Accessed May 15, 2025.